Efficacy and Safety of SR1375 in Adult Patients With CAP

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(29 sites)

China

Fuyang People's Hospital, Fuyang, Anhui

Peking University Third Hospital, Beijing, Beijing Municipality

Zhangzhou Hospital, Zhangzhou, Fujian

Gaozhou People's Hospital, Gaozhou, Guangdong

The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong

The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong

Nanfang Hospital, Guangzhou, Guangdong

The First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong

Yulin First People's Hospital, Yulin, Guangxi

The First Hospital of Hebei Medical University, Shijiazhuang, Hebei

Daqing Longnan Hospital, Daqing, Heilongjiang

Daqing People's Hospital, Daqing, Heilongjiang

Shangqiu People's Hospital, Shangqiu, Henan

Henan Provincial People's Hospital, Zhengzhou, Henan

Yueyang Central Hospital, Yueyang, Hunan

Nanjing First Hospital, Nanjing, Jiangsu

Jiangxi Provincial People's Hospital, Nanchang, Jiangxi

The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi

Yanbian University Affiliated Hospital, Yanbian, Jilin

Dalian Central Hospital, Dalian, Liaoning

The Second Hospital of Dalian Medical University, Dalian, Liaoning

Weifang Second People's Hospital, Weifang, Shandong

Zibo Municipal Hospital, Zibo, Shandong

Zhongshan Hospital, Shanghai, Shanghai Municipality

Shanghai Tongren Hospital, Shanghai, Shanghai Municipality

Shanghai Pulmonary Hospital, Shanghai, Shanghai Municipality

West China Hospital of Sichuan University, Chengdu, Sichuan

The First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan

Lishui Central Hospital, Lishui, Zhejiang